Skip to main content
S&P 5007,712.57+0.28%DOW52,495.88+1.02%NASDAQ26,424.82-0.02%BTC$83,097.00+1.89%ETH$2,455.36+2.50%GOLD$4,138.20-0.11%OIL$98.47+0.66%
Smart Investors Daily
SID Premium
QG

NYSE · QGEN

Qiagen N.V.

Healthcare · Medical - Diagnostics & Research

$46.55

Up+$2.35 (+5.05%)

Updated Oct 21, 2026, 1:27 AM

SID Score

5.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
9.85B
P/E ratio
24.3
Dividend yield
3.24%
52-week range
$32.53 – $57.82
Volume
2.16M
Avg. volume
1.17M

Price performance · QGEN

QGEN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 19, 2026

QGEN closed at $46.55 after 20 trading sessions, up 6.55% for the selected period.

Last close
$46.55
Period change
+6.55%
Period low
$42.04
Period high
$46.55
Daily close
View OHLC price history
QGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 19, 2026$46.18$46.915$45.84$46.552.16M
Oct 16, 2026$46.59$46.75$45.965$46.132M
Oct 15, 2026$45.96$46.485$45.595$46.171.31M
Oct 14, 2026$45.885$46.3677$45.47$45.561.63M
Oct 13, 2026$45.77$45.79$44.97$45.441.44M
Oct 12, 2026$45.68$45.69$44.955$45.311.17M
Oct 9, 2026$44.99$45.61$44.79$45.381.26M
Oct 8, 2026$44.44$44.80$43.65$44.531.56M
Oct 7, 2026$45.61$46.09$44.78$44.792.58M
Oct 6, 2026$47.25$47.28$45.27$45.652.9M
Oct 5, 2026$44.78$46.005$44.46$45.793.05M
Oct 2, 2026$42.445$45.60$42.18$44.754.56M
Oct 1, 2026$43.85$43.87$41.94$42.042.62M
Sep 30, 2026$44.40$44.70$43.76$43.762.32M
Sep 29, 2026$44.08$44.66$44.04$44.404.23M
Sep 28, 2026$44.65$45.525$44.37$45.012.75M
Sep 25, 2026$44.73$44.80$43.995$44.181.41M
Sep 24, 2026$44.08$45.21$44.00$44.561.69M
Sep 23, 2026$43.49$43.92$42.56$43.713.04M
Sep 22, 2026$44.43$44.47$43.615$43.691.45M

Latest QGEN news

The latest Smart Investors Daily articles mentioning QGEN.

Stock researchCompany · Overview

QGEN research

Overview

Company profile and research snapshot.

Company profile

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$53.00
Implied upside
—
Analysts
—
QGEN recent ratings
DateFirmRatingTarget
Oct 14, 2026JP MorganOverweight—
Oct 6, 2026BarclaysOverweight—
Sep 9, 2026UBSNeutral—
Aug 10, 2026CitigroupNeutral—
Aug 7, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

VENLO, Netherlands & GERMANTOWN, Md., October 13, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis prevention, screening and care.

Yahoo · Oct 6, 2026

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

VENLO, Netherlands & GERMANTOWN, Md., October 06, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By